ILMN Jan 2024 370.000 put

OPR - OPR Prix différé. Devise en USD
170,50
0,00 (0,00 %)
À la clôture : 10:36AM EDT
Le graphique des titres n’est pas pris en charge par votre navigateur actuel
Clôture précédente170,50
Ouverture170,50
Offre153,10
Vente167,40
Prix d’exercice370,00
Date d’expiration2024-01-19
Var. jour170,50 - 170,50
Gamme de contratsS.O.
Volume1
Position de placeS.O.
  • PR Newswire

    Illumina livre le premier séquenceur NovaSeq X Plus au Broad Institute

    Illumina Inc. (NASDAQ: ILMN), un leader mondial dans le séquençage de l'ADN et les technologies basées sur les analyses, a annoncé aujourd'hui que son premier système NovaSeq X Plus a récemment été livré au Broad Institute. Alex Aravanis, PhD, directeur de la technologie chez Illumina, en a fait l'annonce aujourd'hui lors d'une présentation à la conférence Advances in Genome Biology and Technology (AGBT) à Hollywood, en Floride. Alex Aravanis a également annoncé des mises à jour très attendues d

  • ACCESSWIRE

    Greenwood Genetic Center: Answering the Unanswered

    Before next-generation sequencing (NGS) came along, children and families with rare and undiagnosed genetic diseases often faced years-long diagnostic odysseys.

  • ACCESSWIRE

    New Virtual Lab for Students Opens Access to Next-Generation Sequencing

    While visiting her grandparents in Florida, 17-year-old Kate frequented a pond near their house and spent time observing the various species of fish living there.

  • ACCESSWIRE

    RNA Sequencing Critical to Identifying Key Fusions for Oncology Patients

    NORTHAMPTON, MA / ACCESSWIRE / November 8, 2022 / Illumina: At the Phoenix Convention Center in Arizona, representatives from Illumina, a global leader in DNA sequencing and array-based technologies, joined approximately 2000 molecular diagnostic ...

  • ACCESSWIRE

    Rarebase Is on the Hunt for Therapeutic Opportunities

    San Francisco Bay Area residents Jainu and Shruti Jogani had their newborn daughter, Reyna, at home for nearly three weeks when they noticed her exhibiting seizure-like symptoms-episodes so quick they weren't able to capture them on video. Standard blood work, MRI scans, and EKGs all came back normal, except for a gene panel for epilepsy.

  • ACCESSWIRE

    Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States

    Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, announced a new research test for genitourinary pathogen and antimicrobial resistance (AMR) identification.

  • ACCESSWIRE

    IGB Gene Drive Aims To Broaden Science Accessibility

    Advances in genomic studies have now permeated all aspects of our lives from agriculture to health and wellness. It is therefore becoming increasingly important to help the community understand these innovations so that they can navigate the increasingly complex realm of genomics. To this end, the outreach team at the Carl R.

  • ACCESSWIRE

    Empowering the Disability Community at Illumina

    "The Spoon Theory," a personal story by patient advocate Christine Miserandino, imagines "spoons" as a measurement of one's daily energy to illustrate what it's like to ration that energy.

  • ACCESSWIRE

    Can Genomics Stop the World's Leading Cause of Death?

    For decades, cardiovascular disease has remained the number-one cause of death. In 2019 alone, nearly 18 million people around the world died from cardiovascular diseases (CVDs), which include disorders such as coronary heart disease, heart failure, and cerebrovascular disease.

  • ACCESSWIRE

    Francis deSouza Recognized as 3BL Media's Responsible CEO of the Year for Innovation and ESG Integration

    Illumina CEO, Francis deSouza received the award for 3BL Media's 2022 Responsible CEO of the Year: Innovation and ESG Integration. 3BL Media presents Responsible CEO of the Year awards to corporate executives who embody leadership in delivering on their environmental, social, and governance (ESG) commitments.

  • ACCESSWIRE

    Illumina To Host Second Annual Virtual ESG Investor Event on Friday, October 28, 2022

    Illumina, Inc. (NASDAQ:ILMN) announced that it will host its second annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:30 am Pacific Time (12:30 pm Eastern Time), Friday, October 28, 2022.

  • ACCESSWIRE

    Australia Begins a Big Push To Sequence Underserved Populations

    Australia's Centre for Population Genomics (CPG), a collaboration between the Garvan Institute of Medical Research and the Murdoch Children's Research Institute, has launched a new initiative to engage diverse communities in genomic research.

  • Business Wire

    Illumina Ventures annonce l’expansion de son équipe Europe

    SAN FRANCISCO, August 05, 2022--Illumina Ventures, société de capital-risque indépendante axée sur les soins de santé dans le cadre d’un partenariat stratégique avec Illumina (NASDAQ : ILMN), a annoncé aujourd’hui l’ajout de quatre nouveaux membres à son équipe européenne. Arnaud Autret, PhD, MSc, sera directeur et chef des opérations européennes, William Byrne, PhD, sera associé – Europe, et Ronan Byrne et Ivan Coulter, PhD, BSc, agiront en qualité que conseillers en capital-risque – Europe.

  • PR Newswire

    Illumina investit dans un fonds de capital-risque de 30 millions de livres sterling pour faire progresser les avancées concernant la santé humaine

    L'investissement de LifeArc, Illumina et Illumina Ventures financera des startups dans le domaine de la génomique pour les diplômés d'Illumina Accelerator CambridgeSAN DIEGO, 30 juin 2022/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), un leader mondial dans le séquençage de l'ADN et les technologies basées sur des réseaux, a annoncé aujourd'hui sa participation à Time Boost Capital I LP, un fonds de capital-risque en génomique de 30 millions de livres sterling destiné à fournir un financement équ